SCHEMBL12779918

SCHEMBL12779918

Cc1cnccc1-c1cnn2cc(-c3ccc(OCCN4CCN(C)CC4)cc3)cnc12

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMP4 P12644 7/20 0.81
KDR P35968 9/20 0.66
FLT1 P17948 8/20 0.66
PRKAB1 Q9Y478 8/20 0.66
PRKAB2 O43741 7/20 0.66
PRKAG1 P54619 7/20 0.66
PRKAA2 P54646 7/20 0.66
PRKAA1 Q13131 7/20 0.66
PRKAG3 Q9UGI9 7/20 0.66
PRKAG2 Q9UGJ0 7/20 0.66
ACVR1 Q04771 7/20 0.66
BMPR1B O00238 5/20 0.66
ACVRL1 P37023 5/20 0.66
LCK P06239 4/20 0.66
SRC P12931 4/20 0.66
EPHA2 P29317 4/20 0.66
RPS6KA1 Q15418 4/20 0.66
MKNK1 Q9BUB5 4/20 0.66
ACVR1B P36896 3/20 0.66
BMPR1A P36894 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11953442 0.90 BMP4 (1.00) BMP4KDRFLT1PRKAB1PRKAB2
SCHEMBL2059672 0.88 BMP4 (1.00) BMP4KDRFLT1PRKAB1PRKAB2
SCHEMBL12779946 0.85 BMP4 (0.83) BMP4KDRFLT1PRKAB1PRKAB2
SCHEMBL11953878 0.83 BMP4 (0.83) BMP4KDRFLT1PRKAB1PRKAB2
SCHEMBL11953444 0.83 BMP4 (1.00) BMP4KDRPRKAB1ACVR1BMPR1B
SCHEMBL24788025 0.81 BMP4 (0.72) BMP4KDRFLT1PRKAB1PRKAB2
SCHEMBL24788026 0.81 BMP4 (0.66) BMP4KDRFLT1PRKAB1PRKAB2
Dorsomorphin SCHEMBL463155 0.79 KDR (1.00) BMP4KDRFLT1PRKAB1PRKAB2
Dorsomorphin SCHEMBL2119244 0.79 KDR (0.98) BMP4KDRFLT1PRKAB1PRKAB2
Dorsomorphin SCHEMBL17845800 0.79 KDR (0.98) BMP4KDRFLT1PRKAB1PRKAB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398118-A1 METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE KEROS THERAPEUTICS, INC. 2023-12-14 US disclosed
US-20230372390-A1 METHODS OF TREATING LYMPHOPENIA KEROS THERAPEUTICS, INC. 2023-11-23 US disclosed
US-20170014349-A1 TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2017-01-19 US disclosed
US-9045484-B2 Inhibitors of the BMP signaling pathway THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-06-02 US disclosed
US-20140038953-A1 COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE THE GENERAL HOSPITAL CORPORATION (US) 2014-02-06 US disclosed
US-20140011805-A1 INHIBITORS OF THE BMP SIGNALING PATHWAY THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2014-01-09 US disclosed
US-8507501-B2 Inhibitors of the BMP signaling pathway THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-08-13 US disclosed
US-20110053930-A1 INHIBITORS OF THE BMP SIGNALING PATHWAY THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053930-A1 INHIBITORS OF THE BMP SIGNALING PATHWAY BMP1, BMP2K, BMP2 BMP4 4/4885KDR 260/4885FLT1 162/4885
US-20170014349-A1 TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE BMP2, BMP1, BMP6 BMP4 6/4885KDR 203/4885FLT1 324/4885
US-20230398118-A1 METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE BMPR2, BMP1, BMP2 BMP4 7/4885KDR 138/4885FLT1 193/4885
US-20140011805-A1 INHIBITORS OF THE BMP SIGNALING PATHWAY BMP1, BMP2K, BMP2 BMP4 4/4885KDR 260/4885FLT1 162/4885
US-20140038953-A1 COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE APOB, BMP1, LDLR BMP4 8/4885KDR 251/4885FLT1 121/4885
US-20230372390-A1 METHODS OF TREATING LYMPHOPENIA HAMP, BMPR2, BMP2 BMP4 17/4885KDR 1564/4885FLT1 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.